GlassScriptPhysician profile
Sheikh Masood
NPI 1669422812
$3,148.92
in general payments reported to CMS, 2019-2025
24 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $464 · 2021: $98.11 · 2022: $311 · 2023: $588 · 2024: $720 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.95 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $518.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $410.70 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $349.66 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $323.76 | 2019-2025 | Farxiga, Lokelma |
| Lilly USA, LLC | $246.59 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Akebia Therapeutics INC | $215.79 | 2019-2025 | Vafseo |
| Ardelyx, INC. | $199.92 | 2023-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $143.50 | 2019-2025 | |
| Baxter Healthcare | $124.74 | 2019 | |
| Fresenius USA Marketing, INC. | $93.57 | 2020-2024 | Velphoro |
| Amgen INC. | $89.46 | 2024-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $77.79 | 2024-2025 | Tarpeyo |
| Kyowa Kirin, INC. | $54.19 | 2023 | Crysvita |
| Glaxosmithkline, LLC. | $53.18 | 2023 | Jesduvroq, Benlysta |
| Horizon Therapeutics Plc | $46.67 | 2021-2023 | Krystexxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $36.36 | 2019-2023 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.03 | 2023-2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $28.25 | 2023 | Acthar |
| Alnylam Pharmaceuticals INC. | $19.72 | 2020 | |
| Corcept Therapeutics | $19.28 | 2025 | Korlym |
| Cormedix INC. | $17.57 | 2025 | Defencath |
| Bard Peripheral Vascular, INC. | $15.43 | 2020 | |
| Travere Therapeutics, INC. | $14.85 | 2022-2023 | |
| Daiichi Sankyo INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheikh Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.